IOL CHEMICALS & PHARMACEUTICALS LTD. Q4 FY26 Results

Summary

IOL Chemicals and Pharmaceuticals Limited announced the approval of its Audited Standalone and Consolidated Financial Statements for the quarter and year ended March 31, 2026, by its Board of Directors. The Company's statutory auditors provided an Unmodified Opinion on these financial results. Additionally, the Board approved significant capacity expansion initiatives, including the installation of a new 6000 MTPA plant for 'Triacetin' and an increase in 'Pantoprazole' manufacturing capacity from 240 MTPA to 276 MTPA. Both expansion projects are notable for being fully funded through internal accruals, signaling prudent financial management and a strategic focus on product portfolio diversification and strengthening market presence.

Key Highlights

1. 1

   The Board of Directors approved the Audited Standalone and Consolidated Financial Statements for the quarter and financial year ended March 31, 2026.

2. 2

   The Company's Statutory Auditors, M/s. Ashwani & Associates, issued an Unmodified Opinion on the Audited Standalone and Consolidated Financial Results.

3. 3

   The 39th Annual General Meeting (AGM) of the members has been scheduled for September 2, 2026, to be held through Video Conferencing/Other Audio Visual Means.

4. 4

   The Board approved the installation of a new manufacturing plant for 'Triacetin' at the existing Barnala facility, with an initial installed capacity of 6000 MTPA.

5. 5

   An enhancement of the installed manufacturing capacity for 'Pantoprazole' was approved, increasing it from the existing 240 MTPA to 276 MTPA at the Barnala plant.

6. 6

   Both the new Triacetin plant and the Pantoprazole capacity enhancement projects are entirely funded through internal accruals.